Sarcopenia in Older Patients in the Acute Hospital Setting

Rambam Health Care Campus

Status: Enrolling

Conditions: Frailty; Sarcopenia

Treatments: Device: Virtual Gate Device (VGD)

Study type: Interventional

Funder types: Other

Identifiers

NCT04092790

0053-18-RMB

Details and patient eligibility

About

This study will assess whether the use of technology using the Virtual Gate Device (VGD) will prevent or minimize the development of hospital acquired Sarcopenia resulting from Immobilization.

Full description

Modern advances in prevention, medical care, and treatments have resulted in an ever-increasing life expectancy and aging of the population. As a result, it is imperative that health care professionals and policy makers develop strategies and new technologies that enable older people to enjoy their advancing years in good health.

Sarcopenia, an age-related decrease in muscle mass, is a major factor in functional decline and frailty and leads to poor quality of life and increased health care costs in older age groups. Because sarcopenia is known to be exacerbated at the time of acute hospital admission, the development of new technologies for the prevention and diagnosis of sarcopenia will have important ramifications in promoting healthy aging in both the acute care and ambulatory settings.

A pilot interventional self-controlled study will be performed in an internal medicine department (internal medicine ward Het) at the Rambam Health Care Campus in Haifa.

Subjects will be evaluated for the risk of sarcopenia by acceptable screening instruments as well as B-mode portable ultrasound. They will then be treated using a stocking-like Virtual Gait Device (VGD) which will be applied to one randomly-assigned lower limb. The VGD is a technology that uses fussy-logic technology to stimulate calf muscles in synchrony with the patient's heartbeat, enabling a virtual gait in patients who have limited mobility.

Confidentiality will be achieved by applying a unique identifier to each trial subject in accordance with Good Clinical Practice standards.

Enrollment: 50 estimated patients

Sex: All

Ages: 75+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients 75 years of age and older.
• Patients admitted with an acute infection (clinically from a respiratory or urinary source).
• Expected length of hospitalization of at least 4 days.
• Patients who are conscious and cognitively able to provide written informed consent as determined by a score of 0 on the 4AT scale

Exclusion criteria

• Male and female patients under 75 years of age.
• Expected length of hospitalization of less than 4 days.
• A condition limiting the use of the virtual gate device (VGD) due to factors relating to discomfort or safety, including but not limited to: fracture, amputation, local infection, pain, paralysis of one or both lower limbs, cardiac arrhythmia or cardiac pacemaker.
• Patients who are unable to or do not provide informed consent for participation.
• A score 1 or more on the 4AT scale.

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Virtual Gate Device (VGD)

Experimental group

Description:

The Virtual Gait Device (VGD) is a technology that uses fussy-logic technology to stimulate calf muscles in synchrony with the patient's heartbeat, enabling a virtual gait in patients who have limited mobility. The stocking-like device is especially useful in older patients who are acutely hospitalized and thus at risk for sarcopenia. While physical activity and physical resistance training are well-documented as preventive measures for sarcopenia, active physical exercise is an unrealistic option for most acutely hospitalized, mobility-limited, older patients. The VGD is a practical alternative that is simple to operate. One pilot study in the orthopedics department in Hadassah Medical Center in Jerusalem, Israel was performed on patients with fractured ankles with the goal of muscle wasting prevention. The VGD will be provided by the manufacturer for use in this pilot clinical study.

Treatment:

Device: Virtual Gate Device (VGD)